Biopharmaceuticals
The North American Millers' Association (NAMA) believes the risk of adulteration from genetic material not approved for food and feed entering the food chain is unacceptable. NAMA believes that preventing such adulteration is the responsibility of the technology developer and the U.S. government because the prevention of such adulteration is totally within their control. NAMA recommends:
- An expansion of current physical confinement system procedures to include a physical separation from all like-commodities or containment under monitored greenhouse conditions, sufficient to guarantee a 100 percent effective isolation from like commodities used in food and feed.
- A temporal separation at pollination based on growing and planting periods.
- Security procedures that prevent deliberate contamination.
- Mandatory liability insurance coverage to indemnify all downstream traders, handlers, processors and food manufacturers for the full cost of recall, destruction and brand degradation as a result of gene flow or other release of genetic material into the food or feed industries.
- The use of dedicated equipment in all steps of the plant-made pharmaceutical and industrial product manufacturing.
- The creation of USDA/GIPSA validated test methods for the presence of the specific plant-made pharmaceutical and industrial products before approval of field test permits.
- Compliance and enforcement procedures that guarantee a zero level of contamination including the creation of a third party auditing system of compliance.
last updated May 14, 2004
Read more:
100 Percent Containment Required for Biotech Pharmaceutical and Industrial Products, March 25, 2004
NAMA Calls for Tight Regulation of Plant-Made Pharmaceuticals, February 13, 2003
NAMA Applauds BIO Announcement as Important First Step, November 5, 2002
Back to Top